Serotonin dysregulation in Fragile X Syndrome: Implications for treatment

Alicia C. Hanson, Randi J Hagerman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Fragile X Syndrome (FXS) is a trinucleotide repeat disorder that results in the silencing of the Fragile X Mental Retardation 1 gene (FMR1), leading to a lack of the FMR1 protein (FMRP). FMRP is an mRNA-binding protein that regulates the translation of hundreds of mRNAs important for synaptic plasticity. Several of these pathways have been identified and have guided the development of targeted treatments for FXS. Here we present evidence that serotonin is dysregulated in FXS and treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline may be beneficial for individuals with FXS, particularly in early childhood.

Original languageEnglish (US)
Pages (from-to)110-117
Number of pages8
JournalIntractable and Rare Diseases Research
Volume3
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Fragile X Syndrome
Serotonin
Fragile X Mental Retardation Protein
Trinucleotide Repeats
Sertraline
Messenger RNA
Neuronal Plasticity
Serotonin Uptake Inhibitors
Protein Biosynthesis
Intellectual Disability
Carrier Proteins
Proteins
Genes

Keywords

  • fragile X mental retardation protein
  • Fragile X Syndrome
  • selective serotonin reuptake inhibitors
  • sertraline

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Serotonin dysregulation in Fragile X Syndrome : Implications for treatment. / Hanson, Alicia C.; Hagerman, Randi J.

In: Intractable and Rare Diseases Research, Vol. 3, No. 4, 2014, p. 110-117.

Research output: Contribution to journalArticle

@article{b44804b1a71349b388c1e96c3cc0393a,
title = "Serotonin dysregulation in Fragile X Syndrome: Implications for treatment",
abstract = "Fragile X Syndrome (FXS) is a trinucleotide repeat disorder that results in the silencing of the Fragile X Mental Retardation 1 gene (FMR1), leading to a lack of the FMR1 protein (FMRP). FMRP is an mRNA-binding protein that regulates the translation of hundreds of mRNAs important for synaptic plasticity. Several of these pathways have been identified and have guided the development of targeted treatments for FXS. Here we present evidence that serotonin is dysregulated in FXS and treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline may be beneficial for individuals with FXS, particularly in early childhood.",
keywords = "fragile X mental retardation protein, Fragile X Syndrome, selective serotonin reuptake inhibitors, sertraline",
author = "Hanson, {Alicia C.} and Hagerman, {Randi J}",
year = "2014",
doi = "10.5582/irdr.2014.01027",
language = "English (US)",
volume = "3",
pages = "110--117",
journal = "Intractable and Rare Diseases Research",
issn = "2186-3644",
publisher = "International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.)",
number = "4",

}

TY - JOUR

T1 - Serotonin dysregulation in Fragile X Syndrome

T2 - Implications for treatment

AU - Hanson, Alicia C.

AU - Hagerman, Randi J

PY - 2014

Y1 - 2014

N2 - Fragile X Syndrome (FXS) is a trinucleotide repeat disorder that results in the silencing of the Fragile X Mental Retardation 1 gene (FMR1), leading to a lack of the FMR1 protein (FMRP). FMRP is an mRNA-binding protein that regulates the translation of hundreds of mRNAs important for synaptic plasticity. Several of these pathways have been identified and have guided the development of targeted treatments for FXS. Here we present evidence that serotonin is dysregulated in FXS and treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline may be beneficial for individuals with FXS, particularly in early childhood.

AB - Fragile X Syndrome (FXS) is a trinucleotide repeat disorder that results in the silencing of the Fragile X Mental Retardation 1 gene (FMR1), leading to a lack of the FMR1 protein (FMRP). FMRP is an mRNA-binding protein that regulates the translation of hundreds of mRNAs important for synaptic plasticity. Several of these pathways have been identified and have guided the development of targeted treatments for FXS. Here we present evidence that serotonin is dysregulated in FXS and treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline may be beneficial for individuals with FXS, particularly in early childhood.

KW - fragile X mental retardation protein

KW - Fragile X Syndrome

KW - selective serotonin reuptake inhibitors

KW - sertraline

UR - http://www.scopus.com/inward/record.url?scp=85010120460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010120460&partnerID=8YFLogxK

U2 - 10.5582/irdr.2014.01027

DO - 10.5582/irdr.2014.01027

M3 - Article

AN - SCOPUS:85010120460

VL - 3

SP - 110

EP - 117

JO - Intractable and Rare Diseases Research

JF - Intractable and Rare Diseases Research

SN - 2186-3644

IS - 4

ER -